A Phase 2/3 Study of Evorpacept (ALX148) in Combination With Trastuzumab, Ramucirumab,
and Paclitaxel in Patients With Advanced HER2-overexpressing gastric/GEJ adenocarcinoma.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT05002127.
Locations matching your search criteria
United States
Tennessee
Nashville
Vanderbilt University/Ingram Cancer CenterStatus: Temporarily closed to accrual
Name Not Available
This is a randomized phase 2 (open-label) / 3 (blinded), international, multi-center
study of patients with metastatic HER2-overexpressing gastric/GEJ adenocarcinoma that has
progressed on or after prior HER2-directed therapy and fluoropyrimidine- or
platinum-containing chemotherapy and are suitable for chemotherapy (2nd-line or
3rd-line). Approximately 450 adult patients are expected to be enrolled in the study
across both phases.
The Sponsor has decided not to proceed with the Phase 3 portion of the study due to
strategic considerations.
Lead OrganizationALX Oncology
